Biospecifics Technologies Corp., a biopharmaceutical company, announced the results of their Chien-802 clinical trial this month. Designed to evaluate the efficacy of injectable collagenase in canine lipoma, the trial showed "dramatic reductions" in the subcutaneous lipomas following the injections.
Canine lipomas are encapsulated fat deposits that occur under the skin, restricting motion and making the pet uncomfortable. According to a 1999 JAVMA report (1), lipomas occur in approximately 1.7 million dogs in the U.S. The only proven therapy for this condition is surgical excision of the lipoma, which involves the use of general anesthesia.
Biospecifics Technologies also announced in the release the initiation of a larger clinical trial, Chien-803, for the same indication. This trial will enroll 25 canines, each having two or more lipomas.